31,512 Shares in Elanco Animal Health Incorporated $ELAN Bought by MRA Advisory Group

MRA Advisory Group acquired a new position in Elanco Animal Health Incorporated (NYSE:ELAN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 31,512 shares of the company’s stock, valued at approximately $776,000.

Other institutional investors have also recently bought and sold shares of the company. NewEdge Advisors LLC raised its stake in shares of Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after purchasing an additional 627 shares during the period. Root Financial Partners LLC boosted its holdings in shares of Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after buying an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. bought a new position in Elanco Animal Health during the fourth quarter valued at about $41,000. Torren Management LLC bought a new position in Elanco Animal Health during the fourth quarter valued at about $46,000. Finally, Bessemer Group Inc. increased its holdings in Elanco Animal Health by 33.2% during the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after buying an additional 525 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 4,971 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the transaction, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This represents a 2.98% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rajeev A. Modi acquired 4,911 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average cost of $20.35 per share, with a total value of $99,938.85. Following the purchase, the insider directly owned 160,812 shares of the company’s stock, valued at $3,272,524.20. This trade represents a 3.15% increase in their position. The SEC filing for this purchase provides additional information. 1.14% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have commented on ELAN shares. TD Cowen lifted their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. KeyCorp raised their price target on shares of Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday. Citigroup lifted their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Weiss Ratings raised shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $29.09.

Elanco Animal Health Trading Down 8.9%

Shares of Elanco Animal Health stock opened at $22.06 on Friday. Elanco Animal Health Incorporated has a 12-month low of $16.15 and a 12-month high of $27.98. The company has a market cap of $11.02 billion, a price-to-earnings ratio of -53.80, a PEG ratio of 1.45 and a beta of 1.67. The company has a current ratio of 2.05, a quick ratio of 1.12 and a debt-to-equity ratio of 0.58. The company’s 50-day moving average price is $24.70 and its 200-day moving average price is $24.09.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. Elanco Animal Health’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities analysts expect that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.